Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OXA-REPLACE trial of mFOLFOX6 plus nivolumab in previously untreated unresectable or recurrent esophageal cancer
jRCTs051240108Phase 2Active, not recruiting
- Start
- Sep 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab, fluorouracil, oxaliplatin and levoleucovorin in esophageal cancer. Primary endpoint: Overall response rate. Started Sep 2024; status: active, not recruiting.
02
Drugs
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on jRCTs051240108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051240108.